Comparative Evaluation of Olopatadine 0.01% Combined Fluorometholone 0.1% Treatment Versus Olopatadine 0.01% Combined Ketorolac 0.4% Treatment in Patients with Acute Seasonal Allergic Conjunctivitis

References

• Katelaris CH, Bielory L. Evidence-based study design in ocular allergy trials. Curr Opin Allergy Clin Immunol 2008;8:484–488
   PubMed Web of Science ®Google Scholar
• Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011;11:471–476
   PubMed Web of Science ®Google Scholar
• Irkec MT, Bozkurt B. Molecular immunology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2012;12:534–539
   Google Scholar
• Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993;38:115–132
   PubMed Web of Science ®Google Scholar
• Jun J, Bielory L, Raizman MB. Vernal conjunctivitis. Immunol Allergy Clin North Am 2008;28:59–82
   PubMed Web of Science ®Google Scholar
• Kari O, Saari KM. Diagnostics and new developments in the treatment of ocular allergies. Curr Allergy Asthma Rep 2012;12:232–239
   Google Scholar
• Katelaris CH. Ocular allergy in the Asia Pacific region. Asia Pac Allergy 2011;1:108–114
   PubMedGoogle Scholar
• Leonardi A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs 2005;10:505–520
   PubMedGoogle Scholar
• Leibowitz HM. The red eye. N Engl J Med 2000;343:345–351
   PubMed Web of Science ®Google Scholar
• Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 2005;5:437–440
   PubMed Web of Science ®Google Scholar
• Church MK, McGill JI. Human ocular mast cells. Curr Opin Allergy Clin Immunol 2002;2:419–422
   Google Scholar
• Calonge M, Montero JA, Herreras JM, Ramón JJ, Pastor JC. Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Ann Allergy Asthma Immunol 1996;77:124–130
   PubMed Web of Science ®Google Scholar
• Greiner JV, Mundorf T, Dubiner H, Lonsdale J, Casey R, Parver L, et al. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. Am J Ophthalmol 2003;136:1097–1105
   PubMed Web of Science ®Google Scholar
• Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmocother 2004;5:1979–1994
   PubMed Web of Science ®Google Scholar
• Varguez-Rodríguez ME, Hernández-López A, Gómez-Dávila Rde L. Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis. Rev Med Inst Mex Seguro Soc 2009;47:399–404
   PubMedGoogle Scholar
• Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl 2000;230:52–55
   PubMedGoogle Scholar
• Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin 2007;23:1445–1452
   PubMed Web of Science ®Google Scholar
• Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr Med Res Opin 2004;20:1167–1173
   PubMed Web of Science ®Google Scholar
• Hida WT, Nogueira DC, Schaefer A, Dantas PE, Dantas MC. Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis. Arq Bras Oftalmol 2006;69:851–856
   PubMedGoogle Scholar
• Bielory BP, Perez VL, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2010;10:469–477
   PubMed Web of Science ®Google Scholar
• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108–133
   PubMed Web of Science ®Google Scholar
• Bielory BP, O'Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmol 2012;90:399–407
   PubMed Web of Science ®Google Scholar
• Figus M, Fogagnolo P, Lazzeri S, Capizzi F, Romagnoli M, Canovetti A, et al. Treatment of allergic conjunctivitis:results of a 1-month, single-masked randomized study. Eur J Ophthalmol 2010;20:811–818
   PubMed Web of Science ®Google Scholar
• Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther 2012;34:1259–1272
   PubMed Web of Science ®Google Scholar
• Khurana S, Sharma N, Agarwal T, Chawla B, Velpandian T, Tandon R, Titiyal JS. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. Eye Contact Lens 2010;36:210–214
   PubMedGoogle Scholar
• Akingbehin AO. Comparative study of the intraocular pressure effects of fluorometholone 0.1% versus dexamethasone 0.1%. Br J Ophthalmol 1983;67:661–663
   Web of Science ®Google Scholar
• Rajpal RK, Digby D, D'Aversa G, Mah F, Hollander DA, Conway T. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review. J Ocul Pharmacol Ther 2011;27:305–308
   Google Scholar
• Lu E, Fujimoto LT, Vejabul PA, Jew RL. Steroid-induced ocular hypertension with loteprednol etabonate 0.2% – a case report. Optometry 2011;82:413–420
   Google Scholar
• Bilgihan K, Gürelik G, Akata F, Hasanreisoglu B. Fluorometholone-induced cataract after photorefractive keratectomy. Ophthalmologica 1997;211:394–396
   Google Scholar
• Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand Suppl 1999;228:47–52
   Google Scholar
• Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003;81:378–382
   PubMedGoogle Scholar
• Fujishima H, Fukagawa K, Takano Y, Tanaka M, Okamoto S, Miyazaki D, et al. Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. J Ocul Pharmacol Ther 2009;25:265–270
   PubMed Web of Science ®Google Scholar